Study of the specific activity of anthelmintic drug “Ap-helmin”
DOI:
https://doi.org/10.24959/ubphj.20.271Keywords:
anthelmintic drugs, albendazole, praziquantel, nematodosis, cestodosis, pharmacological studiesAbstract
Topicality. The problem of infectious and parasitic diseases and, in particular, helminthiases of various etiologies, has acute social significance in the modern world. The active spread of pathogens, including those that are not typical for certain regions and countries, neglection of personal hygiene rules and problems in the field of medical insurance lead to an increase in the incidence of diseases among the population both in countries with insufficient levels of medical development, and in highly developed countries.
Aim. To study the specific pharmacological activity of an anthelmintic drug that combines albendazole and praziquantel in a ratio of (1 : 4) using spontaneous paraspidoderosis (nematodosis) and hymenolepidosis (cestodosis) in white rats as an example.
Materials and methods. The studies have been carried out in the coproscopic laboratory of the Department of Parasitology of the Kharkov State Zooveterinary Academy according to the standardized Fulleborn method and “Method for the quantitative determination of helminth eggs” (patent No. 9265).
Results and discussion. The results obtained indicate the absolute effectiveness of the study drug. The results of a clinical examination of animals showed that the behavior of the animals did not change (natural), the intake of food and water was normal, the visible mucous membranes were pale pink, the skin was holistic, without damage, and the skin was elastic.
Conclusions. Based on the results obtained, it can be concluded that the studied drug under the conditional name “AP-helmin” has a high level of specific pharmacological activity.References
Helmintozy – chy ye aktualnoiu tsia problema? (n.d.). Available at: http://www.gvkg.kiev.ua/index.php/informatsiia-dlia-khvorykh-fiz/778-helmintozy-chy-ie-aktualnoiu-tsia-problema
Hlysty – shkidlyvi “kvartyranty” liudyny. (n.d.). Available at: http://www.rouoz.gov.ua/health/prevention/?sid=32
Samura, B. A., Babak, O. Ya., Kolesnyk, Yu. M. (Eds.). (2010). Farmakoterapyia : ucheb. dlia stud. vuzov: 4-e yzd., pererab y dop. Kharkiv: Zolotie stranytsi, 800.
Derzhavnyi reiestr likarskykh zasobiv. (n.d.). Available at: http://www.drlz.com.ua/ibp/ddsite.nsf/all/shlist?opendocument
Nastanova 00020. Askarydoz. (n.d.). Available at: http://guidelines.moz.gov.ua/documents/2918?id=ebm00020&format=pdf
Nastanova 00019. Hostryky (enterobioz). (n.d.). Available at: http://guidelines.moz.gov.ua/documents/2918?id=ebm00019&format=pdf
Nastanova 00021. Kyshkovitsestodozy. (n.d.). Available at: http://guidelines.moz.gov.ua/documents/2918?id=ebm00021&format=pdf
Nastanova 01039. Nematodozy. (n.d.). Available at: http://guidelines.moz.gov.ua/documents/2918?id=ebm01039&format=pdf
Nastanova 01038. Stronhiloidoz. (n.d.). Available at: http://guidelines.moz.gov.ua/documents/2918?id=ebm01038&format=pdf
Nastanova 01043. Trykhotsefaloz. (n.d.). Available at: http://guidelines.moz.gov.ua/documents/2918?id=ebm01043&format=pdf
Tolochko, K., & Vyshnevska, L. (2017). Analysis of the domestic pharmaceutical market of anthelmintic medicines. News of Pharmacy, 1 (89), 56–60. http://dx.doi.org/10.24959/nphj.17.2157
Semchenko, K. V., Vyshnevska, L. I. (2019). Pat. № u201910233. Antyhelmintnyi zasib na osnovi albendazolu ta prazykvantelu. Ukraina, MPK (2019.1): A61K 31/4184, A61K 31/47, A61P 33/00.
Semchenko K. V., Vyshnevska L. I. (2019). Pat. № a201910236. Antyhelmintnyi zasib na osnovi albendazolu ta prazykvantelu; Ukraina, MPK (2019.1): A61K 31/4184, A61K 31/47, A61P 33/00.
Mazannyi, O. V., Byrka, V. I., Prykhodko, Yu. O. (2005). Pat. na korysnu model № 9265, Ukraina MPK51, G01N 33/487. № u200502006.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).